Liver transplantation: Normothermic regional perfusion tied to better DCD liver allograft outcome, study reveals

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-10 02:30 GMT   |   Update On 2024-04-10 02:30 GMT
Advertisement

USA: A recent study published in JAMA Surgery reports US liver transplant outcomes after normothermic regional perfusion (NRP) versus standard super rapid recovery.

The findings suggest that NRP improves controlled donation after circulatory death (DCD) liver allograft outcomes and holds the potential to increase DCD organ use.

"The multicenter cohort study comprisng136 livers recovered with super rapid recovery (SRR) and 106 livers recovered with NRP showed comparable patient and graft survival in liver transplant recipients of DCD donors recovered by NRP versus SRR, with reduced ischemic cholangiopathy rates in NRP recipients," the researchers reported.

Advertisement

Normothermic regional perfusion is an emerging recovery modality for transplantable allografts from controlled donation after circulatory death (cDCD) donors. In the US, only 11.4% of liver recipients transplanted from a deceased donor receive a cDCD liver.

NRP holds the potential to safely expand the US donor pool with improved transplant outcomes versus standard super rapid recovery. Considering this, Aleah L. Brubaker, University of California San Diego, La Jolla, California, and colleagues aimed to assess outcomes of US liver transplants using controlled donation after circulatory death livers recovered with NRP versus standard SRR.

For this purpose, the researchers conducted a retrospective, observational cohort study to compare liver transplant outcomes from cDCD donors recovered by NRP versus SRR. They collated outcomes of cDCD liver transplants from 2017 to 2023 from 17 US transplant centers. The livers recovered by SRR and NRP (thoracoabdominal NRP [TA-NRP] and abdominal NRP [A-NRP]) were included.

Seven transplant centers used NRP, allowing liver allografts to be transplanted at 17 centers; 10 centers imported livers recovered via NRP from other centers.

The study's primary outcome was ischemic cholangiopathy (IC). Secondary endpoints were early allograft dysfunction (EAD), primary nonfunction (PNF), posttransplant length of stay (LOS), biliary anastomotic strictures, and patient and graft survival.

The study included 242 cDCD livers: 136 recovered by SRR and 106 recovered by NRP (TA-NRP, 79 and A-NRP, 27). Median NRP and SRR donor age was 30.5 years and 36 years, respectively.

The findings of the study were as follows:

  • Median (IQR) posttransplant LOS was significantly shorter in the NRP cohort (7 days vs 10 days).
  • PNF occurred only in the SRR allografts group (n = 2). EAD was more common in the SRR cohort (56.1% versus 36.4%).
  • Biliary anastomotic strictures were increased 2.8-fold in SRR recipients (6.7% vs 22.4%).
  • Only SRR recipients had IC (9.0%); IC-free survival by Kaplan-Meier was significantly improved in NRP recipients.
  • Patient and graft survival were comparable between cohorts.

In conclusion, there was comparable patient and graft survival in liver transplant recipients of cDCD donors recovered by NRP vs SRR, with reduced rates of IC, EAD, and biliary complications in NRP recipients.

The feasibility of TA-NRP and A-NRP implementation across multiple US transplant centers supports increasing NRP adoption to improve organ use, risk of wait-list mortality, and access to transplants.

Reference:

Brubaker AL, Sellers MT, Abt PL, et al. US Liver Transplant Outcomes After Normothermic Regional Perfusion vs Standard Super Rapid Recovery. JAMA Surg. Published online April 03, 2024. doi:10.1001/jamasurg.2024.0520


Tags:    
Article Source : JAMA Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News